- RecruitingPHASE2
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
This study looks at new treatments for advanced stomach or oesophageal cancer with a specific protein called HER2. We're testing a new drug, trastuzumab deruxtecan, by itself or with other common cancer medicines to see if it's safe and effective.
For: Gastric CancerUnited States · Brazil · Canada - Active not recruitingPHASE3
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
This study is looking at new ways to treat a type of breast cancer that doesn't have certain hormone receptors or HER2 protein, called triple-negative or hormone receptor-low/HER2-negative breast cancer. It tests two different treatment plans using new and existing medicines before and after surgery.
For: Breast CancerUnited States · Australia · Austria - Active not recruitingPHASE3
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
This study is for people with a type of lung cancer that can't be removed by surgery. It tests new drug combinations (Durvalumab with Oleclumab, or Durvalumab with Monalizumab) after standard treatment to see if they can help stop the cancer from coming back or getting worse.
For: Non-Small Cell Lung CancerUnited States · Australia · Brazil - Active not recruitingPHASE3
Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer
This study looks at a new drug, durvalumab, and standard chemotherapy (FLOT) for stomach or food pipe cancer that can be removed by surgery. It aims to see if this combination, given before and after the operation, is safe and effective.
For: Gastrointestinal Neoplasms · Esophagogastric JunctionUnited States · Argentina · Belgium - Active not recruitingPHASE1, PHASE2
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
This study is looking at new combinations of medicines for HER2-positive breast cancer that has spread. It aims to see how safe and effective these combinations are in patients whose advanced breast cancer has come back or spread.
For: Metastatic Breast CancerUnited States · Australia · Brazil - Active not recruitingPHASE3
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
This study is looking at new ways to treat early-stage lung cancer that hasn't spread. It's testing if a drug called durvalumab, or another drug called osimertinib, when given after standard radiation therapy, can help improve outcomes for patients.
For: Carcinoma, Non-Small-Cell LungUnited States · Australia · Belgium - Active not recruitingPHASE1, PHASE2
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
This study looks at new drug combinations for metastatic triple-negative breast cancer. It combines standard treatment with new medicines (like Durvalumab) to see if they're safe and work well together for patients whose cancer has spread.
For: Triple Negative Breast NeoplasmsUnited States · Canada · Poland - Active not recruitingPHASE3
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
This study, called POSEIDON, is testing new drug combinations for people with a type of lung cancer called non-small cell lung cancer (NSCLC). It's comparing usual chemotherapy with combinations of two new drugs, durvalumab and tremelimumab, to see if they work better.
For: Non Small Cell Lung Cancer NSCLCUnited States · Brazil · Bulgaria - Active not recruitingPHASE3
CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)
The CompARE trial is testing new treatments for a type of throat cancer called oropharyngeal cancer. It compares different ways of using radiotherapy, surgery, and immunotherapy to see if they improve survival and quality of life for adults with more advanced forms of this cancer.
For: Oropharyngeal CancerIreland · United Kingdom - Active not recruitingPHASE3
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
This study looks at new ways to treat advanced lung cancer that can't be removed by surgery. It combines standard chemotherapy and radiation with newer drugs, pembrolizumab and olaparib, to see if they can improve survival compared to current treatments.
For: Lung Neoplasms · Carcinoma, Non-Small-Cell LungUnited States · Argentina · Canada - Active not recruitingPHASE1, PHASE2
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
This study looks at new drug combinations for advanced cancers. We want to see if they're safe, how well they work, and what effects they have on the body. It involves different stages to find the best doses and see benefits.
For: Advanced Solid TumorsUnited States · Australia · Belgium - RecruitingPHASE3
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
This study is looking at new treatments for advanced bile duct cancer that has a specific marker called HER2. We want to see if these new medicines work better and are safer than standard treatments for patients who haven't had treatment for their advanced cancer before.
For: Biliary Tract CancerUnited States · Australia · Austria - RecruitingPHASE3
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
This study is testing a new drug called Zanidatamab for people with advanced HER2-positive biliary tract cancer. It compares this new drug combined with standard treatments to standard treatments alone, to see if it's more effective and safe.
For: Biliary Tract CancerUnited States · Argentina · Belgium - RecruitingPHASE3
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
This study is testing a new drug, olomorasib, for a specific type of lung cancer (NSCLC) with a KRAS G12C gene change. It checks if olomorasib, combined with standard treatments, works better than standard treatments alone for people with either resected or unresectable cancer.
For: Carcinoma, Non-Small-Cell LungUnited States · Australia · Austria - Active not recruitingPHASE2
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
This study looks at new ways to treat advanced non-small cell lung cancer that hasn't spread after initial treatment. It compares two treatments: Durvalumab alone, and Durvalumab combined with Olaparib, to see if the combination helps patients live longer and better.
For: Non-small Cell Lung Cancer NSCLCUnited States · Belgium · Hungary - RecruitingPHASE3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
This study looks at new treatments for a type of breast cancer called triple-negative. It compares a new drug, Dato-DXd, sometimes with Durvalumab, against standard chemotherapy with Pembrolizumab for patients whose cancer has come back locally or spread.
For: Breast CancerUnited States · Argentina · Australia - Active not recruitingPHASE2
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer
This study is looking at whether a drug called durvalumab, given after surgery, chemo, and radiotherapy, can help people with bladder cancer. We want to see if it stops the cancer from growing or helps cancer cells die.
For: Bladder CancerCanada · Spain · United Kingdom - Active not recruitingPHASE3
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
This study looks at new treatments (Durvalumab, Tremelimumab) for a type of lung cancer, Small Cell Lung Cancer, after initial strong treatment. It aims to see if these drugs can stop the cancer from coming back.
For: Small Cell Lung CancerUnited States · Argentina · Belgium - RecruitingPHASE3
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
This study is for adults with a certain type of lung cancer (Stage II-IIIB non-small cell lung cancer) that has a specific genetic change (HER2 mutation) and has been fully removed by surgery. It compares a new daily tablet called zongertinib with standard treatments to see if it can stop the cancer from coming back.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE2
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer
This study looks at new treatments for triple negative breast cancer that hasn't fully responded to initial chemotherapy. We're testing if medicines, given briefly before surgery, can start to shrink the cancer or change it in helpful ways.
For: Breast Neoplasm · Triple Negative Breast Cancer (TNBC) · HRDUnited Kingdom - Active not recruitingPHASE3
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)
This study is looking at a new treatment called Durvalumab for advanced bile duct and gallbladder cancer. It's given alongside standard chemotherapy to see if it helps patients live longer and better. It's for people whose cancer is advanced and hasn't been treated yet, or has come back after a long time.
For: Biliary Tract NeoplasmsUnited States · Argentina · Bulgaria - Active not recruitingPHASE3
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
This study is testing a new combination of treatments for adults with advanced lung cancer (NSCLC) that hasn't spread to the brain or spine and doesn't have certain genetic changes. It compares this new treatment to a standard one, hoping it works better.
For: NSCLCUnited States · Austria · Brazil - Active not recruitingPHASE3
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
This study looks at a new way to treat muscle-invasive bladder cancer using a drug called Durvalumab alongside standard chemotherapy. It aims to see if this combination, given before and after surgery, can improve treatment outcomes and safety for patients.
For: Muscle Invasive Bladder CancerUnited States · Australia · Belgium - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
This study looks at new treatments for a type of lung cancer that hasn't spread widely but can't be removed by surgery. It aims to see how well these medicines work and if they are safe after standard initial treatments.
For: Non-Small Cell Lung CancerUnited States · Australia · Belgium - Active not recruitingPHASE3
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
This study looks at new drug combinations for stage I-III triple-negative breast cancer that hasn't fully responded to initial treatment. It compares Dato-DXd with or without Durvalumab against standard treatments to see if they're more effective and safe.
For: Breast CancerUnited States · Belgium · Brazil - Active not recruitingPHASE2
ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss
This study looks at new treatments for gynaecological cancers that have come back. It tests a drug called ceralasertib, sometimes with olaparib or durvalumab, to see how well they work in different types of cancer cells, especially those with a specific gene change called ARID1A loss.
For: Gynaecological CancersCanada · United Kingdom - RecruitingPHASE3
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
This study is looking at new treatments for a type of bladder cancer that has a high chance of coming back after surgery. It compares two new drugs, Dato-DXd and Rilvegostomig, with standard treatments to see if they are safer and more effective.
For: High-risk Muscle Invasive Urothelial CarcinomaUnited States · Australia · Brazil - RecruitingPHASE3
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
This study is looking at two different treatments, pumitamig and durvalumab, for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that can't be removed by surgery. It's for patients who have already had chemotherapy and radiation.
For: Non-small Cell Lung Cancer (NSCLC)United States · Argentina · Australia - RecruitingPHASE3
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
This study is looking at new ways to treat advanced bile duct cancer. It compares two drug combinations: rilvegostomig with chemotherapy, and durvalumab with chemotherapy, to see which is safer and works better as a first treatment.
For: Biliary Tract CancerUnited States · Australia · Belgium - Active not recruiting
Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and Canada
This study looks at existing medical records of people in Europe and Canada with a type of lung cancer called non-small cell lung cancer (NSCLC) who had surgery. It helps us understand how a treatment called immunotherapy is used before or after their operation, and how they got on.
For: Non-Small Cell Lung CancerUnited Kingdom - Active not recruitingPHASE3
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
This study is testing new drug combinations for a type of kidney cancer called Papillary Renal Cell Carcinoma (PRCC). It compares a mix of savolitinib and durvalumab, or just durvalumab, against a standard treatment, sunitinib, for advanced PRCC linked to a specific genetic change.
For: Papillary Renal Cell CarcinomaUnited States · Argentina · Australia - Active not recruitingPHASE2
Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors
This study looks at new drug combinations for certain advanced cancers. It aims to understand how these drugs affect cancer at a genetic level and in the body. It combines an immunotherapy drug with another type of cancer drug.
For: Mismatch Repair Proficient Colorectal Cancer · Pancreatic Adenocarcinoma · LeiomyosarcomaCanada - Active not recruitingPHASE2
Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC
This study is looking at new drug combinations for metastatic lung cancer. It combines durvalumab and tremelimumab, which are treatments that help your body's immune system fight cancer, sometimes with standard chemotherapy. We want to see if these new combinations are more effective.
For: Lung Cancer MetastaticAustralia · Canada - RecruitingPHASE2
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
This study looks at new drug combinations before and after surgery for early-stage lung cancer. It aims to see if these treatments are safe and work well to help people with non-small cell lung cancer.
For: Non-small Cell Lung CancerUnited States · Belgium · Canada - Active not recruitingPHASE2
Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. a Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group
This study is testing if adding a drug called durvalumab to standard treatment (chemotherapy and radiation) works better for advanced anal cancer. Researchers want to see if this new combination improves how well people respond to treatment.
For: Anal Cancer · Anal Carcinoma · Anal Cancer Stage IIIAustria · Germany · Switzerland - Active not recruitingPHASE3
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
This study is looking at a new combination of medicines, tarlatamab and durvalumab, for people with advanced small-cell lung cancer. It wants to see if this combination helps people live longer compared to durvalumab alone, after their initial chemotherapy treatment.
For: Extensive-Stage Small-Cell Lung Cancer · Small-Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE2
A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
This study looks at new treatments for advanced bladder cancer that can’t be removed by surgery and where standard chemotherapy isn't an option. It tests two drugs, Durvalumab and Olaparib, to see if they are safe and effective.
For: Urinary Bladder NeoplasmsUnited States · Canada · Russia - Active not recruiting
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
This study looks at how well different treatments work for adults with liver cancer that can't be removed by surgery. Researchers are collecting health information from medical records to find the best next steps for people who have already had a specific type of first-line therapy.
For: Unresectable Hepatocellular CarcinomaUnited States · Argentina · Brazil - RecruitingPHASE2
Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery
This study looks at a new way to treat early oesophageal cancer using a combination of immunotherapy (durvalumab), chemotherapy, and radiotherapy. The aim is to help patients avoid major surgery, while still effectively treating their cancer.
For: Esophagus AdenocarcinomaGermany - RecruitingPHASE3
Renal Adjuvant MultiPle Arm Randomised Trial
This study looks at new treatments for kidney cancer (renal cell carcinoma) after surgery. It compares two drugs, durvalumab and tremelimumab, given alone or together, against standard monitoring. The aim is to see if these drugs can stop the cancer from coming back or help people live longer.
For: Renal Cell CarcinomaUnited Kingdom - RecruitingPHASE3
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
This study looks at a new treatment combination for a type of advanced lung cancer called extensive stage small-cell lung cancer (ES-SCLC). It compares a combination including tarlatamab with a standard treatment to see if it helps people live longer.
For: Small-cell Lung Cancer · Extensive Stage Small-cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE2
Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN
This study looks at a new way to treat certain head, neck, and throat cancers. It combines a drug called durvalumab with a different type of radiation therapy. The aim is to see if this new approach controls cancer just as well as standard treatment, with fewer side effects.
For: HNSCCFrance - Active not recruitingPHASE2
Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma
This study looks at new drug combinations (Durvalumab and Tremelimumab with FOLFIRI chemotherapy) for advanced stomach or food pipe cancer that has already been treated. It aims to see how well patients respond and if these combinations can help people live longer.
For: Gastric Adenocarcinoma · Gastric CancerFrance - RecruitingPHASE1, PHASE2
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
This study is testing a new drug, IDE849, for certain cancers including a type of lung cancer. It aims to see if it's safe and effective, sometimes using it alone and sometimes with other medicines.
For: Small-cell Lung Cancer · Neuroendocrine Carcinomas · Solid Tumor Show to Express DLL3United States · Australia · Brazil - RecruitingPHASE2, PHASE3
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
This study is looking into new treatments for advanced liver cancer (hepatocellular carcinoma). It compares new drug combinations, livmoniplimab with budigalimab, against existing treatments to find the best dose and see how well they work and what side effects they might have.
For: Hepatocellular CarcinomaUnited States · France · Italy - Active not recruitingPHASE2
Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:
This study is for women with a certain type of breast cancer (Luminal B). It tests new ways to combine chemotherapy, radiation, and new drugs (durvalumab and oleclumab) before surgery to see if they work better at treating the cancer.
For: Luminal BBelgium · France - RecruitingPHASE1, PHASE2
DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr
This study, called DURANCE, is testing a new combination treatment for bladder cancer that hasn't spread into the muscle. It combines a vaccine (S-488210/S-488211) with an immunotherapy drug (durvalumab) to see if it's safe and effective in people who haven't responded well to previous treatments.
For: Bladder CancerUnited Kingdom - Active not recruitingPHASE3
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
This study is looking at a new drug called durvalumab, combined with standard chemotherapy, for people with advanced bile duct cancer. It aims to see if this combination is safe and works better than current treatments in shrinking tumours and improving health.
For: Biliary Tract CancerUnited States · France · Germany - RecruitingPHASE3
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
This study, called NIAGARA-2, is looking at a new way to treat bladder cancer that has grown into the muscle. It combines a drug called durvalumab with standard chemotherapy, given before and after surgery. The aim is to see if this combination improves treatment.
For: Urinary Bladder Neoplasms · Immune Checkpoint Inhibitors · MethotrexateAustralia · Brazil · Canada - Active not recruitingPHASE2
Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)
This study looks at new ways to treat a type of lung cancer that can be removed by surgery. It combines standard chemotherapy with a new immunotherapy drug (durvalumab) and different types of radiation therapy to see if this mix works better.
For: Non-small Cell Lung Cancer · NSCLCGermany · Switzerland